Centerpoint Medical Center LLC

Summary

Centerpoint Medical Center LLC is a medical facility located in Independence, Missouri. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Centerpoint Medical Center LLC is involved with conducting 141 clinical trials across 243 conditions. There are 4 research doctors associated with this hospital, such as Suman Kambhampati, Rakesh Gaur, Mohammad Mozayen, and Aruna Rokkam.

Top PIs

Clinical Trials running at Centerpoint Medical Center LLC

Breast cancer

Breast Cancer

Brain Tumor

Cardiotoxicity

Meningioma

Orthostatic Intolerance

Atrial Fibrillation

Brain Metastasis

HER2 Positive

No change needed.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.

Recruiting

2 awards

Phase 3

23 criteria

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

Marker-Directed Monitoring

for Breast Cancer

This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.

Recruiting

1 award

N/A